Aridis Pharmaceuticals, Inc. announced that it has entered into a note purchase agreement for the private placement of a secured promissory note in the aggregate principal amount of $5,250,000 which carries an original issue discount of $250,000 for gross proceeds of $5,000,000 on November 23, 2021. The transaction included participation from Streeterville Capital, LLC. The note bears interest at the rate of 6% per annum and matures on November 23, 2023. The note is secured by the company?s MabIgX assets. Beginning on May 23, 2021, the investor has the right to redeem all or any portion of the note up to the maximum monthly redemption amount which is $450,000. Payments of each redemption amount must be made in cash. All interest calculations hereunder shall be computed on the basis of a 360-day year comprised of twelve (12) thirty (30) day months, shall compound daily and shall be payable in accordance with the terms of this note. The company can prepay all or any portion of the outstanding amount at a rate of 105% of the portion of the outstanding balance company elects to prepay if prepayment occurs on or before the three-month anniversary of the issuance date; (b) 107.5% of the portion of the outstanding balance company elects to prepay if prepayment occurs after the three-month anniversary of the issuance date but on or before the six-month anniversary of the issuance date and (c) 110% of the outstanding balance if the prepayment occurs after the six-month anniversary of the issuance date.